Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Morphosys Ag (NASDAQ:MOR) on Wednesday, setting a price target of EUR140, which is approximately 631.86% above the present share price of $22.76.
Shu expects Morphosys Ag to post earnings per share (EPS) of $0.00 for the first quarter of 2021.
The current consensus among 1 TipRanks analysts is for a Moderate Buy rating of shares in Morphosys Ag, with an average price target of $166.57.
The analysts price targets range from a high of $166.57 to a low of $166.57.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $22 million and a net profit of -$62.03 million. The company's market cap is $2.98 billion.
According to TipRanks.com, Berenberg Bank analyst Zhiqiang Shu is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 5.4% and a 37.04% success rate.
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery (NASDAQ:DISCA) segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.